Abstract
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
Keywords: Left ventricular dysfunction, doxorubicin, oxidant stress.
Current Cardiology Reviews
Title:Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volume: 7 Issue: 4
Author(s): Maria Volkova and Raymond Russell
Affiliation:
Keywords: Left ventricular dysfunction, doxorubicin, oxidant stress.
Abstract: Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
Export Options
About this article
Cite this article as:
Volkova Maria and Russell Raymond, Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment, Current Cardiology Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157340311799960645
DOI https://dx.doi.org/10.2174/157340311799960645 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Improving Nutritional Quality of Plant Proteins Through Genetic Engineering
Current Genomics Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Umbilical Cord Tissue Mesenchymal Stem Cells: Characterization and Clinical Applications
Current Stem Cell Research & Therapy Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Phenotypic Characterization of a Family With An In-frame Deletion in the DMD Gene and Variable Penetrance
Current Gene Therapy Plant Extracts and Isolated Compounds Reduce Parameters of Oxidative Stress Induced by Heavy Metals: An up-to-Date Review on Animal Studies
Current Pharmaceutical Design CYP-Mediated Clozapine Interactions: How Predictable Are They?
Current Drug Metabolism The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets Ultrasound Techniques for Drug Delivery in Cardiovascular Medicine
Current Drug Discovery Technologies Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Editorial [Hot Topic:The Metabolic Treatment of Coronary Artery Disease and Heart Failure(Executive Editor: Pericle Di Napoli)]
Current Pharmaceutical Design EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease
Current Pharmaceutical Design An In-Silico Investigation of Anti-Chagas Phytochemicals
Current Clinical Pharmacology